Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Prediction of Postdural Puncture Headache

10 de julio de 2026 actualizado por: Amasya University

The Effectiveness of Inflammatory Indices in Predicting Postdural Puncture Headache

The primary objective of this study is to evaluate the effectiveness of inflammation index (pan-immune inflammation value, systemic immune inflammation index, and systemic inflammatory response index) values, calculated from routine pre- and post-operative blood test (hemogram) results of pregnant women undergoing cesarean section under spinal anesthesia, in predicting postdural puncture headache. Significant results will allow for the early identification of the population at risk of developing PPH and the implementation of preventive measures. The secondary objectives of the study are to evaluate the effects of factors such as demographic data (age, height, weight, and body mass index) obtained from patient records and the hospital information system, number of births, blood group, infant birth weight, smoking, previous history of postdural puncture headache (PPH), or headache in general, on the development of postdural puncture headache (PPH), to determine the frequency of PPH, and to identify the symptoms accompanying PPH.

Descripción general del estudio

Estado

Reclutamiento

Descripción detallada

This study is a prospective observational clinical research aiming to evaluate the effectiveness of inflammation index values, calculated from routine blood tests (hemogram) performed before and after surgery in pregnant women undergoing cesarean section under spinal anesthesia, in predicting postdural puncture headache. Spinal anesthesia (SA) is the most commonly preferred regional anesthesia method in cesarean sections due to its rapid onset and effective sensory-motor blockade, but it can lead to complications that restrict maternal comfort in the postoperative period. The most frequently observed of these complications is postdural puncture headache (PPH), which is characteristically worsened in the upright position, relieved in the supine position, and develops within 5 days. PPH, usually located in the frontal or occipital region, is a clinical condition that may be accompanied by symptoms such as nausea, vomiting, weakness, tinnitus, photophobia, and neck pain. Incidence; The type of needle used varies depending on age, gender, and technical factors . The fundamental mechanism in the pathophysiology of PPH is intracranial hypotension resulting from cerebrospinal fluid (CSF) leakage and the subsequent traction in the brain tissue. Cerebral vasodilation and systemic neuroinflammatory response are also thought to contribute to this process . The physiological systemic inflammatory response observed during pregnancy plays a critical role in the maternal immune system's development of immune tolerance against the fetus and the sustainability of the pregnancy. During this process, neutrophilia, relative lymphopenia, and increased monocyte activation are particularly observed, and these immunological changes are characterized by pro-inflammatory and anti-inflammatory phases that differ according to the trimesters of pregnancy .Systemic inflammatory response has been shown to have significant effects not only on infectious processes but also on nociceptive mechanisms and tissue healing. Immune system components such as macrophages, T-lymphocytes, and mast cells, along with pro-inflammatory mediators like tumor necrosis factor (TNF), interleukin-1 (IL-1), IL-6, and IL-8, are reported to directly contribute to pain pathogenesis . In recent years, pan-immune inflammation value, systemic immune-inflammation index, and systemic inflammatory response index have emerged as cost-effective and easily accessible next-generation biomarkers enabling holistic assessment of inflammation. These indices, calculated from complete blood count (hemogram) parameters using the formulas (neutrophil count x monocyte count x platelet count / lymphocyte count), (platelet count x neutrophil count / lymphocyte count), and (neutrophil count x monocyte count / lymphocyte count), respectively, have been proven to have high prognostic value in predicting various pathophysiological processes in extensive cohort studies . The main objective of this study, planned with the prediction that the physiological inflammatory shift during pregnancy may increase susceptibility to PPH by raising the pan-immune inflammation value, systemic immune-inflammation index, and systemic inflammatory response index values above basal levels, is; The aim of this study is to investigate the predictive value of the aforementioned inflammatory index levels in predicting PPH in pregnant women undergoing cesarean section under spinal anesthesia. Finding significant results will allow for the identification of pregnant women at high risk and the development of early treatment strategies for those predicted to be at high risk.

Tipo de estudio

De observación

Inscripción (Estimado)

260

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Osman O Kılınç, ass prof
  • Número de teléfono: +905067352859
  • Correo electrónico: zxgr03@gmail.com

Ubicaciones de estudio

      • Amasya, Turquía (Türkiye), 05100
        • Reclutamiento
        • Amasya University Training and Research Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto

Acepta Voluntarios Saludables

No

Método de muestreo

Muestra no probabilística

Población de estudio

Pregnant women undergoing cesarean section under spinal anesthesia

Descripción

Inclusion Criteria:

  • . Pregnant women who are of a cognitive level capable of giving informed consent
  • Pregnant women aged 18-45 who have undergone elective cesarean section
  • Term (37 weeks and above) pregnant women
  • Patients with an American Society of Anesthesiologists (ASA) physical status score of 2 (ASA II)

Exclusion Criteria:

  • History of active infection or chronic inflammatory disease
  • History of steroid or immunomodulatory drug use
  • Presence of coagulopathy or hematological disorder
  • Presence of preeclampsia/HELLP syndrome
  • Those who received blood transfusions during and after surgery

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
Patients with postdural puncture headache
Patients with postdural puncture headache after cesarean section
Patients without postdural puncture headache
Patients without postdural puncture headache after cesarean section

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
The predictive role of inflammation indices for postdural puncture headache.
Periodo de tiempo: 5 days
  • The correlation between the preoperative basal panimmune inflammation value, systemic immune-inflammation index, and systemic inflammatory response index values and the development of PPH will be statistically evaluated.
  • Sensitivity and specificity evaluation will be performed for basal panimmune inflammation value, systemic immune-inflammation index, and systemic inflammatory response index values in those who develop PPH.
5 days

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
PPH incidence
Periodo de tiempo: 5 days
The incidence of PPH developing after postdural puncture will be investigated.
5 days

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

15 de junio de 2026

Finalización primaria (Estimado)

15 de noviembre de 2026

Finalización del estudio (Estimado)

15 de diciembre de 2026

Fechas de registro del estudio

Enviado por primera vez

1 de julio de 2026

Primero enviado que cumplió con los criterios de control de calidad

10 de julio de 2026

Publicado por primera vez (Actual)

16 de julio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de julio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de julio de 2026

Última verificación

1 de julio de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • mmk05

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Ethical reasons within the scope of patient privacy

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

3
Suscribir